Ohcanbohtosat - Seppo Ylä‐Herttuala

Aiddostahte ozu
  1. 1
    Glybera's Second Act: The Curtain Rises on the High Cost of Therapy

    Glybera's Second Act: The Curtain Rises on the High Cost of Therapy Dahkki Seppo Ylä‐Herttuala

    Almmustuhtton 2015
    Viečča ollesdeavstta Viečča ollesdeavstta
    Editorial
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Endgame: Glybera Finally Recommended for Approval as the First Gene Therapy Drug in the European Union

    Endgame: Glybera Finally Recommended for Approval as the First Gene Therapy Drug in the European Union Dahkki Seppo Ylä‐Herttuala

    Almmustuhtton 2012
    Viečča ollesdeavstta Viečča ollesdeavstta
    Editorial
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Gene Therapy for Malignant Glioma: Current Clinical Status

    Gene Therapy for Malignant Glioma: Current Clinical Status Dahkki Kalevi Pulkkanen, Seppo Ylä‐Herttuala

    Almmustuhtton 2005
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Current Status of Cardiovascular Gene Therapy

    Current Status of Cardiovascular Gene Therapy Dahkki Tuomas T. Rissanen, Seppo Ylä‐Herttuala

    Almmustuhtton 2007
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Gene Therapy Used in Cancer Treatment

    Gene Therapy Used in Cancer Treatment Dahkki Thomas Wirth, Seppo Ylä‐Herttuala

    Almmustuhtton 2014
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Cardiovascular Gene Therapy: Past, Present, and Future

    Cardiovascular Gene Therapy: Past, Present, and Future Dahkki Seppo Ylä‐Herttuala, Andrew H. Baker

    Almmustuhtton 2017
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    Progress and prospects: hurdles to cardiovascular gene therapy clinical trials

    Progress and prospects: hurdles to cardiovascular gene therapy clinical trials Dahkki Marja Hedman, Juha Hartikainen, Seppo Ylä‐Herttuala

    Almmustuhtton 2011
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    Biology of vascular endothelial growth factors

    Biology of vascular endothelial growth factors Dahkki Himadri Roy, Shalini Bhardwaj, Seppo Ylä‐Herttuala

    Almmustuhtton 2006
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Promoting blood vessel growth in ischemic diseases: challenges in translating preclinical potential into clinical success

    Promoting blood vessel growth in ischemic diseases: challenges in translating preclinical potential into clinical success Dahkki Galina Dragneva, Petra Korpisalo, Seppo Ylä‐Herttuala

    Almmustuhtton 2013
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    Adenoviral Gene Therapy Vectors in Clinical Use—Basic Aspects with a Special Reference to Replication-Competent Adenovirus Formation and Its Impact on Clinical Safety

    Adenoviral Gene Therapy Vectors in Clinical Use—Basic Aspects with a Special Reference to Replication-Competent Adenovirus Formation and Its Impact on Clinical Safety Dahkki Aleksi J. Leikas, Seppo Ylä‐Herttuala, Juha Hartikainen

    Almmustuhtton 2023
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    Expression of LDL Receptor, VLDL Receptor, LDL Receptor–Related Protein, and Scavenger Receptor in Rabbit Atherosclerotic Lesions

    Expression of LDL Receptor, VLDL Receptor, LDL Receptor–Related Protein, and Scavenger Receptor in Rabbit Atherosclerotic Lesions Dahkki Timo P. Hiltunen, Jukka Luoma, T. Nikkari, Seppo Ylä‐Herttuala

    Almmustuhtton 1998
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    Nucleic Acid–Based Therapies for Atherosclerosis

    Nucleic Acid–Based Therapies for Atherosclerosis Dahkki Petri I. Mäkinen, Anna‐Kaisa Ruotsalainen, Seppo Ylä‐Herttuala

    Almmustuhtton 2020
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    Antioxidant Gene Therapy for Cardiovascular Disease

    Antioxidant Gene Therapy for Cardiovascular Disease Dahkki Anna‐Liisa Levonen, Elisa Vähäkangas, Jonna K. Koponen, Seppo Ylä‐Herttuala

    Almmustuhtton 2008
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart?gene therapy

    Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart?gene therapy Dahkki Jaakko O. Markkanen, Tuomas T. Rissanen, Annukka M. Kivelä, Seppo Ylä‐Herttuala

    Almmustuhtton 2004
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    Autoantibodies Against Oxidized Low-Density Lipoprotein and Cardiolipin in Patients With Coronary Heart Disease

    Autoantibodies Against Oxidized Low-Density Lipoprotein and Cardiolipin in Patients With Coronary Heart Disease Dahkki Arja T. Erkkilä, Outi Närvänen, Seppo Lehto, Matti Uusitupa, Seppo Ylä‐Herttuala

    Almmustuhtton 2000
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    Angiogenic gene therapy in cardiovascular diseases: dream or vision?

    Angiogenic gene therapy in cardiovascular diseases: dream or vision? Dahkki Seppo Ylä‐Herttuala, Charles R. Bridges, Michael G. Katz, Petra Korpisalo

    Almmustuhtton 2016
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    Differential but Complementary HIF1α and HIF2α Transcriptional Regulation

    Differential but Complementary HIF1α and HIF2α Transcriptional Regulation Dahkki Nicholas Downes, Nihay Laham-Karam, Minna U. Kaikkonen, Seppo Ylä‐Herttuala

    Almmustuhtton 2018
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  18. 18
    Hypoxia induces microRNA miR‐210 in vitro and in vivo

    Hypoxia induces microRNA miR‐210 in vitro and in vivo Dahkki Kati Pulkkinen, Tarja Malm, Mikko P. Turunen, Jari Koıstınaho, Seppo Ylä‐Herttuala

    Almmustuhtton 2008
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  19. 19
    Baculoviruses exhibit restricted cell type specificity in rat brain: a comparison of baculovirus- and adenovirus-mediated intracerebral gene transfer in vivo

    Baculoviruses exhibit restricted cell type specificity in rat brain: a comparison of baculovirus- and adenovirus-mediated intracerebral gene transfer in vivo Dahkki P. Lehtolainen, Kristiina Tyynelä, J Kannasto, Kari J. Airenne, Seppo Ylä‐Herttuala

    Almmustuhtton 2002
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  20. 20
    Challenges in monoclonal antibody-based therapies

    Challenges in monoclonal antibody-based therapies Dahkki Haritha Samaranayake, Thomas Wirth, Diana Schenkwein, J K Räty, Seppo Ylä‐Herttuala

    Almmustuhtton 2009
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: